Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 2
1993 2
1995 2
1996 3
1997 5
1998 6
1999 11
2000 13
2001 12
2002 12
2003 13
2004 5
2005 17
2006 9
2007 9
2008 13
2009 16
2010 24
2011 24
2012 26
2013 28
2014 23
2015 18
2016 19
2017 15
2018 15
2019 21
2020 26
2021 20
2022 19
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

401 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effectiveness of Intranasal Mometasone Furoate vs Saline for Sleep-Disordered Breathing in Children: A Randomized Clinical Trial.
Baker A, Grobler A, Davies K, Griffiths A, Hiscock H, Kubba H, Peters RL, Ranganathan S, Rimmer J, Rose E, Rowe K, Simpson CM, Davidson A, Nixon G, Perrett KP. Baker A, et al. JAMA Pediatr. 2023 Mar 1;177(3):240-247. doi: 10.1001/jamapediatrics.2022.5258. JAMA Pediatr. 2023. PMID: 36648937 Free PMC article. Clinical Trial.
Evidence from small clinical trials suggests that intranasal corticosteroids improve SDB as measured by polysomnography; however, the effect on symptoms and quality of life is unclear. OBJECTIVE: To determine whether intranasal mometasone furoate is more effective t …
Evidence from small clinical trials suggests that intranasal corticosteroids improve SDB as measured by polysomnography; however, the effect …
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P; IRIDIUM trial investigators. Kerstjens HAM, et al. Lancet Respir Med. 2020 Oct;8(10):1000-1012. doi: 10.1016/S2213-2600(20)30190-9. Epub 2020 Jul 9. Lancet Respir Med. 2020. PMID: 32653074 Clinical Trial.
The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoate, indacaterol acetate, and glycopyrronium bromide (MF-IND-GLY) versus ICS-LABA in patients with inadequately controlled asthma. ...
The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoa
Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level.
Lazarus SC, Krishnan JA, King TS, Lang JE, Blake KV, Covar R, Lugogo N, Wenzel S, Chinchilli VM, Mauger DT, Dyer AM, Boushey HA, Fahy JV, Woodruff PG, Bacharier LB, Cabana MD, Cardet JC, Castro M, Chmiel J, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Hastie A, Holguin F, Israel E, Jackson D, Kraft M, LaForce C, Lemanske RF Jr, Martinez FD, Moore W, Morgan WJ, Moy JN, Myers R, Peters SP, Phipatanakul W, Pongracic JA, Que L, Ross K, Smith L, Szefler SJ, Wechsler ME, Sorkness CA; National Heart, Lung, and Blood Institute AsthmaNet. Lazarus SC, et al. N Engl J Med. 2019 May 23;380(21):2009-2019. doi: 10.1056/NEJMoa1814917. Epub 2019 May 19. N Engl J Med. 2019. PMID: 31112384 Free PMC article. Clinical Trial.
However, there was no significant difference in the response to mometasone or tiotropium, as compared with placebo. Among the patients with a low eosinophil level who had a differential treatment response, 57% (95% confidence interval [CI], 48 to 66) had a better response …
However, there was no significant difference in the response to mometasone or tiotropium, as compared with placebo. Among the patient …
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Gevaert P, et al. J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Free article. Clinical Trial.
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. Coprimary end points included change from baseline to week 24 in Nasal Polyp Score (NPS) and Nasal Cong …
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intran …
Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
Daley-Yates PT, Deans A, Mehta R, Sousa AR. Daley-Yates PT, et al. Pulm Pharmacol Ther. 2022 Dec;77:102171. doi: 10.1016/j.pupt.2022.102171. Epub 2022 Oct 13. Pulm Pharmacol Ther. 2022. PMID: 36243386 Clinical Trial.
AIMS: To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), fluticasone propionate (FP) and fluticasone furoate (FF). ...In each study, 24-h serial blood samples were collected and assayed …
AIMS: To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate ( …
Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis.
Chen R, Zheng D, Zhang Y, Sima G. Chen R, et al. Eur Arch Otorhinolaryngol. 2022 Apr;279(4):1691-1699. doi: 10.1007/s00405-021-07085-w. Epub 2021 Sep 30. Eur Arch Otorhinolaryngol. 2022. PMID: 34591150 Review.
PURPOSE: GSP301 is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). This meta-analysis aims to evaluate the efficacy and safety of GSP301 in the treatment of allergic rhinitis. ...
PURPOSE: GSP301 is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroi …
Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
Vaidya S, Ziegler D, Tanase AM, Malmqvist U, Kanniess F, Hederer B, Hosoe M. Vaidya S, et al. Pulm Pharmacol Ther. 2021 Oct;70:102019. doi: 10.1016/j.pupt.2021.102019. Epub 2021 Mar 23. Pulm Pharmacol Ther. 2021. PMID: 33771722 Free article. Clinical Trial.
BACKGROUND: QMF149 is an inhaled fixed-dose combination of indacaterol acetate and mometasone furoate (MF) delivered via Breezhaler, under development for once-daily treatment of asthma. ...
BACKGROUND: QMF149 is an inhaled fixed-dose combination of indacaterol acetate and mometasone furoate (MF) delivered via Breez …
Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials.
Penagos M, Compalati E, Tarantini F, Baena-Cagnani CE, Passalacqua G, Canonica GW. Penagos M, et al. Allergy. 2008 Oct;63(10):1280-91. doi: 10.1111/j.1398-9995.2008.01808.x. Epub 2008 Aug 21. Allergy. 2008. PMID: 18721246 Review.
RATIONALE: Several randomized, double-blind, placebo-controlled clinical trials have demonstrated the efficacy of mometasone furoate nasal spray (MFNS) in the treatment of allergic rhinitis (AR) thus allowing for a meta-analysis to determine the overall treatment ef …
RATIONALE: Several randomized, double-blind, placebo-controlled clinical trials have demonstrated the efficacy of mometasone furoa
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Wenzel S, et al. Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27. Lancet. 2016. PMID: 27130691 Clinical Trial.
Vitamin D supplementation improves the therapeutic effect of mometasone on allergic rhinitis.
Guo M. Guo M. Acta Biochim Pol. 2023 Sep 16;70(3):583-589. doi: 10.18388/abp.2020_6637. Acta Biochim Pol. 2023. PMID: 37716008 Free article. Clinical Trial.
The patients were randomly divided into control and experimental groups, with 70 patients in each group. Mometasone nasal spray was used in both groups, and vitamin D was administered to the experimental group for four weeks. ...It was concluded that vitamin D supplementat …
The patients were randomly divided into control and experimental groups, with 70 patients in each group. Mometasone nasal spray was u …
401 results